News
ANEB
--
0.00%
--
The Unintended Consequences of Ever-Increasing Marijuana Potency
Photo by Tim Foster on Unsplash
Benzinga · 5h ago
CBD-Focused Anebulo Pharma Posts Q4 & Full Year 2021 Earnings, Launching Phase 2 Cannabis Overdose Clinical Trials
Cannabinoid-focused biotech company Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB) announced its financial results Wednesday for the three and 12 months ended June 30.
Benzinga · 4d ago
BRIEF-Anebulo Pharmaceuticals Reports Q4 Loss Per Share Of $1.59
reuters.com · 4d ago
Anebulo Pharmaceuticals Q4 EPS $(1.59)
Anebulo Pharmaceuticals (NASDAQ:ANEB) reported quarterly losses of $(1.59) per share.
Benzinga · 4d ago
Cannabis Edibles are Leading to More Negative Outcomes in Cannabis Users
Photo by camilo jimenez on Unsplash
Benzinga · 09/20 12:13
Anebulo Pharmaceuticals Completes Manufacturing of Drug Candidate For Phase 2 Trial
MT Newswires · 09/13 15:28
CB1 Antagonists as a Solution to the Complicated Problems of Cannabis Over-intoxication
The legalization of recreational cannabis in a number of states is associated with the increasing problem of acute cannabis intoxication (ACI).
Benzinga · 09/13 12:01
Anebulo Pharmaceuticals Announces Completion of Manufacturing of ANEB-001 Capsules for Upcoming Phase 2 Clinical Trial
AUSTIN, Texas, September 13, 2021--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction, today announced the com...
Business Wire · 09/13 12:00
Anebulo Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
AUSTIN, Texas, September 07, 2021--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) ("Anebulo" or the "Company"), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addic...
Business Wire · 09/07 12:00
Anebulo is Developing an Antidote to Cannabis Intoxication
The company Anebulo Pharmaceuticals (NASDAQ: ANEB) is investing in an antidote for cannabis intoxication. The social and medical issues associated with acute cannabis intoxication (ACI) are often underestimated, because of the perceived lack of risk of can...
Benzinga · 09/07 11:04
The Treatment of Cannabis Toxicity
The increasing prevalence and potency of cannabis following the legalization of recreational marijuana sales in a number of states have also increased the rate of emergency room visits associated with the drug. The Nationwide Emergency Department Sample (N...
Benzinga · 08/30 11:32
22nw, Lp Buys Anebulo Pharmaceuticals Inc, Green Plains Inc, Landec Corp, Sells Trinseo SA, ...
GuruFocus News · 08/23 22:38
Cannabis Legalization is Driving an Increase in Related ER Visits
The legalization of both medical use and recreational use of cannabis in the United States has lead to an increase in both availability and potency.
Benzinga · 08/23 12:31
Alcohol, Cannabis and Synergistic Risk
Although cannabis use is considered relatively benign, there is an increasing appreciation of the risks of cannabis over consumption and its burden on the healthcare system. However, there has been less discussion of the risks associated with the simultane...
Benzinga · 08/16 12:39
BRIEF-Anebulo Pharmaceuticals Announces Formation Of Scientific Advisory Board, Names First Two Members
reuters.com · 08/12 12:14
Cannabis Over-Intoxication Results in Millions of Visits to the ER per Year
The burden on the healthcare system from cannabis use is often underappreciated, because many see the risks of smoking marijuana as low. However, there are a very large number of visits to the emergency room every year as a result of cannabis intoxication....
Benzinga · 08/10 19:38
Here's What Anebulo Pharmaceuticals, Inc.'s (NASDAQ:ANEB) Shareholder Ownership Structure Looks Like
Every investor in Anebulo Pharmaceuticals, Inc. ( NASDAQ:ANEB ) should be aware of the most powerful shareholder...
Simply Wall St. · 08/08 07:23
The Underappreciated Risk Of Pediatric Cannabis Overdose
There are major risks associated with the consumption of large amounts of cannabis by young children.
Benzinga · 08/06 13:56
Webull provides a variety of real-time ANEB stock news. You can receive the latest news about Anebulo Pharmaceuticals, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ANEB
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing solutions for people suffering from cannabinoid overdose and substance addiction. The Company's lead product candidate, ANEB-001, is a potent, small molecule cannabinoid receptor antagonist, designed to address the unmet medical need for a specific antidote for cannabinoid overdose. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations. ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within one hour of administration. CB1 antagonists bind to the CB-1 receptor and thereby reverse the action of cannabinoids such as tetrahydrocannabinol (THC). It has completed Phase I trials.